Print page content Print
Increase text size Decrease text size
Text Size
Eff Top Banner

A single injection begins reducing itch within 1 day and continues working for a full month

OVER 80% OF DOGS HAD SUCCESSFUL PRURITUS REDUCTION AT DAY 3

At day 3, greater than 80% of dogs administered Canine Atopic Dermatitis lmmunotherapeutic* achieved treatment success, predefined as owner-assessed ≥20mm reduction in pruritus as scored on the pruritus Visual Analog Scale (VAS).1†

Efficacy chart 1

Mean pruritus scores were very mild to mild starting at day 1 and continuing for a full month

At day 42, owner assessment of pruritus VAS scores remained mild at 37.6 mm (mean baseline, 71.0 mm) for dogs receiving a 2 mg/kg dose of Canine Atopic Dermatitis Immunotherapeutic.1*

Efficacy chart 2

*This product license is conditional. Efficacy and potency test studies in progress.

VAS is an owner-assessed scale that measures itch along a continuum from normal dog (no itch) to extremely severe itch, using numbers from 0-100. VAS scoring instruments were given to owners, accompanied by explanations of how to rank itch, based on the behavior of the animal. Owners ranked itch daily.

Reference: 1. Data on file, Study Report No. C863R-US-12-018. Zoetis LLC.

Eff Bottom Banner

Skin condition begins to improve within 7 days

SKIN CONDITION SCORE REDUCTION WAS SIGNIFICANT AT DAY 14

Significantly more dogs treated with Canine Atopic Dermatitis Immunotherapeutic achieved treatment success (at least a 50% reduction from baseline in CADESI-03) compared to dogs treated with placebo from day 14 of the study.

Efficacy chart 3

Skin condition score reduction was maintained through day 28

Significant improvement in skin condition was noted at the first visit on day 7 (p≤0.05). At day 28, there was a nearly 50% decrease in mean CADESI-03 scores for dogs administered Canine Atopic Dermatitis Immunotherapeutic* (73.7) compared to dogs administered placebo (121.9) (mean baseline for all dogs, 153.9).1

Efficacy chart 4

*This product license is conditional. Efficacy and potency test studies in progress.

Canine Atopic Dermatitis Extent and Severity Index. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and alopecia at 62 body sites.

Reference: 1. Data on file, Study Report No. C863R-US-12-018. Zoetis LLC.


All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2016 Zoetis Services LLC. All rights reserved. CYT-00078

CONTACT US

1-888-963-8471

Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2021 Zoetis Services LLC. All rights reserved.